Stephanie Graff, Associate Director of Global Oncology and Policy at Brown University, shared a post on X:
“NATALEE Adj Ribo shows sustained improvement in IDFS. Hot take (the dreaded cross trial comparison):
NATALEE is a lower risk population, so that long slow follow-up is critical with 50% of HR+ recurrences happening >5 years, and that OS trend is promising.”
More posts about ESMO25.
